恒瑞医药：HRS-7535片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Company Summary - The subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. of Heng Rui Medicine is set to initiate clinical trials for HRS-7535 tablets shortly [1]. - HRS-7535 functions by activating GLP-1 receptors to promote insulin secretion from the pancreas, reduce glucagon secretion, and inhibit gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to a direct reduction in energy intake [1]. Industry Summary - The development of GLP-1 receptor agonists is significant in the treatment landscape for type 2 diabetes (T2DM) and obesity, addressing both metabolic control and weight management [1].